Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA.
Biol Blood Marrow Transplant. 2012 Feb;18(2):309-13. doi: 10.1016/j.bbmt.2011.08.008. Epub 2011 Aug 11.
Pulmonary dysfunction has been well described after myeloablative transplantation with conventional allogeneic donors; however, whether the risk is similar after alternative donor transplantation with cord blood as the stem cell source has not yet been investigated. We performed a retrospective analysis of patients who underwent double cord blood transplantation after myeloablative conditioning. Pulmonary function tests were performed pretransplantation and at day 80, 1 year, and 2 years posttransplantation, with 56 patients included in the final analysis. No significant change from baseline with respect to the mean values and mean change in pulmonary function test values were observed at 1 year posttransplantation. The rate of lung function decline from baseline to 1 year posttransplantation was <5% in 75% patients; mildly abnormal lung function was reported in 58% of the patients. The cumulative incidence of noninfectious pulmonary complications was 9.7%. Future prospective studies are needed to confirm these findings.
在接受清髓性移植和常规异体供体后，肺功能障碍已得到充分描述；然而，在使用脐带血作为干细胞来源的替代供体移植后，风险是否相似尚未得到研究。我们对接受清髓性预处理后进行双份脐带血移植的患者进行了回顾性分析。在移植前、移植后 80 天、1 年和 2 年进行了肺功能检查，最终分析包括 56 例患者。与基线相比，1 年后肺功能检查的平均值和平均值变化没有显著差异。从基线到移植后 1 年，75%的患者肺功能下降率<5%；58%的患者报告肺功能轻度异常。非感染性肺部并发症的累积发生率为 9.7%。需要进行未来的前瞻性研究来证实这些发现。
